Drug therapy for bone metastasis of malignant tumor: theory, progress, and potential
Abstract:
Bone is a common metastatic site of malignancies, caused by the complex interaction between tumor cells and the bone microenvironment. The complicated procedure covers multiple targets for therapeutic strategies against bone metastasis. At the present, only bisphosphonates and denosumab are currently approved for the prevention of skeletal-related events. But it is still ineffective for some patients, and none of them are proven to prolong the overall survival of patients with bone metastasis. Thus, new bone-modifying agents and therapeutic strategies are required. The review aimed to generalize the basic theory of bone metastasis and major put emphasis on the development of fundamental and potential target drugs in the behavior of bone metastasis. The summary of the drug development process helps to provide ideas for finding new and effective treatments for bone metastasis.
Received date: 10/06/2021
Accepted date: 12/29/2021
Ahead of print publish date: 02/02/2022
Issue: 3/2022
Volume: 69
Pages: 504 — 515
Keywords: bone metastasis, bone microenvironment, bone-modifying agents, skeletal-related events
DOI: 10.4149/neo_2021_211006N1412